We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Baxter Intnl. | LSE:BAX | London | Ordinary Share | COM STK $1 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1497J Acambis PLC 25 March 2003 Final instalment of Baxter subscription agreement Cambridge, UK and Cambridge, Massachusetts - 25 March 2003 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that, pursuant to the subscription agreement between Baxter International, Inc. ("Baxter") and Acambis dated 19 September 2000, the fourth and final instalment of the subscription by Baxter for new Acambis ordinary shares has taken place. The subscription agreement provides for Baxter to make four subscriptions totalling #27.8 million at fixed prices between the years 2000 and 2003. The fourth instalment of approximately #7.0 million at the pre-agreed price of 150p per share represents 4,636,391 new Acambis shares. Application has been made to the UK Listing Authority of the Financial Services Authority and the London Stock Exchange for the listing of 4,636,391 ordinary shares of 10p each fully paid, ranking pari passu with the existing ordinary shares, to the Official List. Following this fourth instalment, Baxter's shareholding will increase to 21,349,994 shares, representing 20.6% of Acambis' enlarged issued share capital of 103,738,249 shares. -ends- Enquiries: Acambis plc Lyndsay Wright, Director of Communications Tel: +44 (0) 1223 275 300 Notes to editors: Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognised internationally as the leading producer of smallpox vaccines, Acambis provides governments around the world with the full portfolio of related smallpox vaccine products required to protect their citizens against the threat of smallpox virus being used as a bioterrorist weapon. Acambis is establishing a travel vaccines franchise, including vaccines against yellow fever, Japanese encephalitis, dengue fever and typhoid. Acambis also has the most advanced vaccine in development targeting the West Nile virus, which has spread to over 40 US States in the last three years. Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary listing is on the London Stock Exchange (ACM) and its shares are listed in the form of American Depositary Receipts on Nasdaq (ACAM). More information is available at www.acambis.com. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials and other product development and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk factors" in the Company's Annual Report and Form 20-F for the most recently ended fiscal year, in addition to those detailed in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. This information is provided by RNS The company news service from the London Stock Exchange END AGRJAMLTMMTTMMJ
1 Year Baxter Intnl. Chart |
1 Month Baxter Intnl. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions